Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126340 | 0.83 | SPHK1 (0.40) | SPHK1SPHK2 | |
| SCHEMBL20126253 | 0.83 | HRH3 (0.42) | SPHK1S1PR3NPC1RAB9AMEN1 | |
| SCHEMBL20126218 | 0.76 | SPHK1 (0.36) | SPHK1S1PR3SPHK2NPC1RAB9A | |
| SCHEMBL20126246 | 0.75 | HRH3 (0.37) | SPHK1SPHK2MEN1KMT2A | |
| SCHEMBL7730942 | 0.75 | FAAH (0.47) | S1PR3SPHK2MEN1TP53KMT2A | |
| SCHEMBL7734594 | 0.75 | FAAH (0.47) | S1PR3SPHK2MEN1TP53KMT2A | |
| SCHEMBL7723101 | 0.75 | FAAH (0.47) | S1PR3SPHK2MEN1TP53KMT2A | |
| SCHEMBL7731581 | 0.75 | FAAH (0.47) | S1PR3SPHK2MEN1TP53KMT2A | |
| SCHEMBL7733153 | 0.75 | FAAH (0.47) | S1PR3SPHK2MEN1TP53KMT2A | |
| SCHEMBL20126315 | 0.74 | SPHK1 (0.36) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | SPHK1 1054/4885S1PR3 951/4885SPHK2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.